Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) PT at $191.77

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received an average recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $191.77.

Several brokerages recently issued reports on ASND. Bank of America increased their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Oppenheimer dropped their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday. Stifel Nicolaus increased their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Finally, The Goldman Sachs Group increased their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th.

Ascendis Pharma A/S Price Performance

Shares of ASND stock opened at $129.81 on Wednesday. Ascendis Pharma A/S has a 1 year low of $90.13 and a 1 year high of $161.00. The stock’s 50 day simple moving average is $133.22 and its two-hundred day simple moving average is $132.23. The company has a market cap of $7.87 billion, a PE ratio of -16.07 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. Equities research analysts expect that Ascendis Pharma A/S will post -7.45 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. SG Americas Securities LLC purchased a new position in Ascendis Pharma A/S in the 1st quarter worth $288,000. ProShare Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock valued at $608,000 after buying an additional 361 shares during the last quarter. Bessemer Group Inc. raised its stake in shares of Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 332 shares during the last quarter. Nan Fung Group Holdings Ltd purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at about $2,056,000. Finally, Capital International Investors raised its stake in shares of Ascendis Pharma A/S by 0.5% during the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after buying an additional 10,044 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.